A customs rule written for low value shipments in general was about to become a prescription drug story. The administration is now delaying it by 90 days, STAT reported on October 14, after patient groups and dozens of lawmakers from both parties pressed the White House to rethink it. The delay claim rests on STAT’s reporting alone in the material available to this edition and is graded accordingly; the rule itself is well documented.
The rule suspends the de minimis exemption, which let shipments worth under $800 clear customs with minimal process. From October 22, mailed goods were to require formal entry, added data and a bond guarantee. The stated purpose is enforcement: collecting tariffs and stopping illegal goods, particularly opioids, entering through low value foreign mail. Prescription medicines are not named in the rule, but medicines mailed from licensed international pharmacies fall inside it, and the practical effect for individual patients was expected to be delays, refusals and added cost rather than a clean legal channel with new paperwork.
The scale is not trivial. About 2.3 million US adults reported buying prescription drugs abroad to save money in a 2020 study published in JAMA Network Open, and Canadian pharmacies are the most common route. That puts a customs enforcement measure on a collision course with the administration’s own drug price message, which has rested on most favored nation deals and direct discount channels, landing two weeks before midterm voting.
A 90 day delay moves the decision past the election and past the October 22 cliff, but it does not resolve the underlying conflict: the exemption suspension is indefinite in design, and personal use importation has always lived in enforcement discretion rather than in a legal right. What to watch is whether the administration uses the delay to carve out personal prescriptions formally, or simply lets the rule take effect in January with the same access consequences and less attention on them.